Coronary Heart Disease Clinical Trial
Official title:
Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine
Verified date | July 2016 |
Source | Tel-Aviv Sourasky Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | Israel: Ethics Commission |
Study type | Interventional |
Current guidelines recommend the addition of proton pump inhibitors (PPI) to patients taking
double anti-platelet therapy (Aspirin and Clopidogrel) to prevent upper GI bleeding1. Many
post percutaneous coronary intervention (PCI) patients are treated with dual anti-platelet
medications as well as PPI to prevent upper GI bleeding.
Recently, it was shown that PPI interact with the P450 system in the liver and reduce the
platelet inhibitory effect of Clopidogrel2,3. Clopidogrel is activated by CYP2C19, which
also metabolizes PPI4. Furthermore, a recent article showed increased mortality in patients
taking PPI and clopidogrel compared with patients taking clopidogrel without PPI
protection5. The degree of reduction in the platelet inhibitory properties of clopidogrel
might vary among the different PPI4.
The use of PPI for GI protection in patients treated with dual anti-platelet therapy is not
based on randomized trials, but rather on expert opinion. Since H2 blockers are also
effective in preventing acid secretion and are not known to interact with the P450 system
that affects clopidogrel, the investigators hypothesized that these group of drugs will not
interfere with the positive antiplatelet effects of clopidogrel and therefore will offer a
good alternative treatment option.
Status | Completed |
Enrollment | 63 |
Est. completion date | August 2011 |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Subject is at least 18 years old. 2. Subject is willing to comply with pre-specified follow-up evaluation and can be contacted by telephone. 3. Use of Clopidogrel (>=75mg) and Aspirin(>=75mg) for at least 1 month. Exclusion Criteria: 1. Known allergy to PPI of H2 blockers 2. Known thrombocytopenia or thrombocytopathia 3. Subject is currently enrolled in another investigational study of a new drug, biologic or device at the time of study screening. NOTE: Subjects who are participating in the long term follow-up phase of a previously investigational and now FDA-approved product are not excluded by this criterion. 4. Subject with symptomatic heart failure of LVEF = 25% 5. Acute myocardial infarction within the past 30 days. 6. No acute inflammatory event during the past month (e.g. infection, autoimmune or acute coronary event) 7. Concurrent medical condition with a life expectancy of less than 12 months. 8. Known severe renal failure (serum creatinine level >2.5 mg/dl). 9. History of bleeding diathesis or coagulopathy or inability or unwillingness to receive blood transfusions. 10. Evidence of active gastrointestinal bleeding or a history of such bleeding that is not known to have been treated and proven to have resolved. 11. History of hepatitis (viral, ischemic or chemically-induced); clinical jaundice, history of cirrhosis. 12. Patient treated with anticoagulant medication (Coumadin, LMWH) |
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Israel | Tel Aviv Medical Center | Tel Aviv |
Lead Sponsor | Collaborator |
---|---|
Tel-Aviv Sourasky Medical Center | Tel Aviv Medical Center |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Platelet function as assessed by a CPA system | 6 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Completed |
NCT05088291 -
Application of a New X-ray Protective Device in Coronary Interventional Therapy
|
||
Completed |
NCT03076801 -
Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?
|
N/A | |
Completed |
NCT04584645 -
A Digital Flu Intervention for People With Cardiovascular Conditions
|
N/A | |
Not yet recruiting |
NCT04995159 -
Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
|
N/A | |
Recruiting |
NCT02967718 -
Innovation Research of Differentiation and Treatment Methods Based on CHD Phlegm and Blood Stasis Syndrome
|
N/A | |
Completed |
NCT02888652 -
Study on the Registration of Coronary Heart Disease Patients Undergoing PCI
|
||
Terminated |
NCT02045134 -
Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery
|
N/A | |
Completed |
NCT02163044 -
The Hellenic Postprandial Lipemia Study (HPLS)
|
||
Active, not recruiting |
NCT02244853 -
Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease
|
N/A | |
Completed |
NCT02753829 -
Home-based Cardiovascular Rehabilitation, Maintenance Phase, in Subjects With Coronary Artery Disease
|
N/A | |
Completed |
NCT02440893 -
Understanding the Effect of Metformin on Corus CAD (or ASGES)
|
||
Completed |
NCT01826552 -
Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent
|
Phase 4 | |
Completed |
NCT01920009 -
Impact of Motivational Interviews Within Pharmacy Care Upon Adherence to Cardiovascular Medicines
|
N/A | |
Terminated |
NCT01906957 -
Cognition and Exercise Training
|
N/A | |
Recruiting |
NCT01689688 -
Healing Response to Everolimus-eluting Stent Implantation; Serial Assessment With opticaL Coherence Tomography
|
N/A | |
Completed |
NCT01779401 -
Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients
|
N/A | |
Recruiting |
NCT01456364 -
Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing
|
Phase 4 | |
Recruiting |
NCT01462799 -
COR-PRIM: Problem-based Learning (PBL) After Coronary Heart Disease (CHD) - Long-term Evaluation in Primary Care of Self-care
|
N/A | |
Completed |
NCT01486030 -
Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
|